Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Emactuzumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Bone cancer; Giant cell tumour of tendon sheath; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 14 Mar 2018 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2015 Interim results published in the Lancet Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History